Literature DB >> 24112549

Local chemotherapeutic agents for the treatment of ocular malignancies.

Bruno F Fernandes1, Katerina Nikolitch2, James Coates2, Gustavo Novais2, Alexandre Odashiro2, Patricia P Odashiro2, Rubens N Belfort2, Miguel N Burnier2.   

Abstract

We critically analyze available peer-reviewed literature, including clinical trials and case reports, on local ocular cancer treatments. Recent innovations in many areas of ocular oncology have introduced promising new therapies, but, for the most part, the optimal treatment of ocular malignancies remains elusive.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CIN; PAM; carboplatin; carcinoma; conjunctiva; interferon; melanoma; mytomicin; retinoblastoma

Mesh：

Substances：

Year:  2013        PMID： 24112549     DOI： 10.1016/j.survophthal.2013.01.003

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN： 0039-6257            Impact factor:   6.048


  4 in total

1.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

Review 2.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

3.  Gene-directed enzyme prodrug therapy for localized chemotherapeutics in allograft and xenograft tumor models.

Authors:  K H Carruthers; G Metzger; M J During; A Muravlev; C Wang; E Kocak
Journal:  Cancer Gene Ther       Date:  2014-09-19       Impact factor: 5.987

4.  Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway.

Authors:  Keting Bao; Yongyun Li; Jinlian Wei; Ruoxi Li; Jie Yang; Jiahao Shi; Baoli Li; Jin Zhu; Fei Mao; Renbing Jia; Jian Li
Journal:  Cell Death Dis       Date:  2021-04-07       Impact factor: 8.469
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.